SHR-1701

Phase 3Small molecule

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

SHR-1701 is one of 240 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

239

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaActive, not recruiting

Gastric Cancer (GC)Recruiting

Gastric AdenocarcinomaRecruiting

Gastric Adenocarcinoma and Gastroesophageal Junction AdenocarcinomaRecruiting

Locally Advanced Pancreatic CancerNot yet recruiting

AdenocarcinomaRecruiting

Intrahepatic CholangiocarcinomaNot yet recruiting

Ovarian CancerNot yet recruiting

LymphomaRecruiting

Gastric CancerTerminated

Hepatocellular CarcinomaPreclinical

Active, not recruiting

Gastric Cancer (GC)Phase 2

Recruiting

Gastric AdenocarcinomaPhase 2

Recruiting

Gastric Adenocarcinoma and Gastroesophageal Junction AdenocarcinomaPhase 2

Recruiting

Locally Advanced Pancreatic CancerPreclinical

Not yet recruiting

AdenocarcinomaPhase 2

Recruiting

Intrahepatic CholangiocarcinomaPhase 2

Not yet recruiting

Ovarian CancerPhase 2

Not yet recruiting

LymphomaPhase 2

Recruiting

Gastric CancerPhase 3

Terminated

Showing 10 of 11 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

SHR-1701

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

1 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Cabenuva

GSK

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

SHR2554

NCT06679673

Q3 2027

Phase 2Not yet recruiting

Intrahepatic Cholangiocarcinoma

NCT07147088

Q4 2027

Phase 2Recruiting

Adenocarcinoma

NCT07102901

Q1 2028

N/ARecruiting

Hepatocellular Carcinoma

NCT06893887

Clinical

Trials by Indication[1]

Locally Advanced Solid Tumor2 trials

SHR-1701 in Metastatic or Locally Advanced Solid Tumors

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03710265·206 enrolled

SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03774979·193 enrolled

Nasopharyngeal Carcinoma2 trials

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04282070·91 enrolled

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1/2·NCT05020925·30 enrolled

Gastric Cancer2 trials

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Terminated· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 2/3·NCT05149807·81 enrolled

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Not yet recruiting·—·Phase 2·NCT06881017·140 enrolled

Pancreatic Cancer1 trial

A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1/2·NCT04624217·56 enrolled

Concurrent Chemoradiotherapy1 trial

SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC

Unknown status·SShanghai Chest Hospital·Phase 2·NCT05177497·19 enrolled

18 more indications

Melanoma1 trial

To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma

Unknown status·YYong Chen·Phase 2·NCT05106023·31 enrolled

Patients With Advanced Solid Tumors1 trial

A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1/2·NCT04679038·222 enrolled

Hepatocellular Carcinoma1 trial

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Recruiting·NNanjing Tianyinshan Hospital·N/A·NCT06893887·300 enrolled

SHR25541 trial

SHR-1701 Combined with SHR2554 and BP102 for MCRC

Not yet recruiting·FFudan University·Phase 2·NCT06679673·20 enrolled

Adenocarcinoma1 trial

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT07102901·351 enrolled

Chemotherapy1 trial

A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT04580498·107 enrolled

Ovarian Cancer1 trial

A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer

Not yet recruiting·QQinglei Gao·Phase 2·NCT07355010·104 enrolled

Metastatic1 trial

SHR-1701 in Patients With Recurrent/Metastatic Scchn

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT04650633·130 enrolled

Small Cell Lung Cancer1 trial

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT04884009·106 enrolled

Advanced Solid Tumors1 trial

A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

Completed·AAtridia Pty Ltd.·Phase 1·NCT04324814·41 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.

Not yet recruiting·FFudan University·Phase 2·NCT07147088·36 enrolled

Lymphoma1 trial

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting·—·Phase 1/2·NCT05896046·100 enrolled

Advanced or Metastatic NSCLC1 trial

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Withdrawn·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT04699968

Pancreas Ductal Adenocarcinoma1 trial

A Prospective, Phase II Study of Gemcitabine and Nab-paclitaxel in Combination With Liposomal Irinotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable/Borderline Resectable Pancreatic Cancer.

Active, not recruiting·TThe First Hospital of Jilin University·Phase 2·NCT07806110·62 enrolled

Locally Advanced Pancreatic Cancer1 trial

GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center, Open-Label, Phase Ib/II Trial

Not yet recruiting·WWest China Hospital·Preclinical·NCT07802184·45 enrolled

Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma1 trial

SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: an Exploratory Study

Recruiting·RRuijin Hospital·Phase 2·NCT07384234·60 enrolled

Gastric Adenocarcinoma1 trial

A Prospective Exploratory Study of SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07464756·80 enrolled

Gastric Cancer (GC)1 trial

Safety and Efficacy of Radiotherapy Combined With Chemotherapy and SHR-1701, a PD-L1(Programmed Death-Ligand 1)/TGF-β(Transforming Growth Factor-beta) Bispecific Antibody, in the Treatment of Unresectable Locally Advanced or Metastatic Gastric Cancer

Recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences·Phase 2·NCT07689851·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for SHR-1701. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR-1701 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR-1701. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Suncadia Biopharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

SHR-1701

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Locally Advanced Solid Tumor2 trials

Nasopharyngeal Carcinoma2 trials

Gastric Cancer2 trials

Pancreatic Cancer1 trial

Concurrent Chemoradiotherapy1 trial

Melanoma1 trial

Patients With Advanced Solid Tumors1 trial

Hepatocellular Carcinoma1 trial

SHR25541 trial

Adenocarcinoma1 trial

Chemotherapy1 trial

Ovarian Cancer1 trial

Metastatic1 trial

Small Cell Lung Cancer1 trial

Advanced Solid Tumors1 trial

Intrahepatic Cholangiocarcinoma1 trial

Lymphoma1 trial

Advanced or Metastatic NSCLC1 trial

Pancreas Ductal Adenocarcinoma1 trial

Locally Advanced Pancreatic Cancer1 trial

Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma1 trial

Gastric Adenocarcinoma1 trial

Gastric Cancer (GC)1 trial

References

Drug Info

Quick Facts

Related News